To provide superior treatment options for patients navigating the complexities of diabetes

Mumbai-based pharma major Lupin has announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), including the trademark rights associated with these brands.

Lupin has been marketing ONDERO and ONDERO MET since 2015 in the Indian market as part of a co-marketing agreement with Boehringer Ingelheim India.

In India, an estimated 77 million people above the age of 18 years have Type-2 Diabetes, while nearly 25 million are pre-diabetic, at higher risk of developing diabetes in the future. ONDERO (Linagliptin) and ONDERO MET (Linagliptin + Metformin) are the gold standard in diabetes management. This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes.

"With the acquisition of ONDERO and ONDERO MET, we continue to offer a wide portfolio of products to enable access to medication for patients, and further consolidate our position as a market leader in the anti-diabetes segment,” said Nilesh Gupta, Managing Director, Lupin.